Landos Biopharma analyst ratings
Landos Biopharma analyst ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
08/12/2022 | — | Raymond James | Downgrades | Outperform → Market Perform | |
04/12/2022 | 29.63% | Jefferies | $30 → $1.4 | Downgrades | Buy → Hold |
03/25/2022 | 733.33% | Raymond James | $24 → $9 | Maintains | Outperform |
01/03/2022 | 548.15% | JP Morgan | $15 → $7 | Maintains | Neutral |
11/16/2021 | 1381.48% | SVB Leerink | $20 → $16 | Downgrades | Outperform → Market Perform |
10/20/2021 | 4066.67% | Craig-Hallum | → $45 | Initiates Coverage On | → Buy |
10/19/2021 | 4529.63% | HC Wainwright & Co. | → $50 | Initiates Coverage On | → Buy |
09/23/2021 | 3511.11% | JonesTrading | → $39 | Initiates Coverage On | → Buy |
07/30/2021 | 3140.74% | Raymond James | $33 → $35 | Maintains | Outperform |
03/01/2021 | 2862.96% | Jefferies | → $32 | Initiates Coverage On | → Buy |
03/01/2021 | 1474.07% | JP Morgan | → $17 | Initiates Coverage On | → Neutral |
03/01/2021 | 2955.56% | Raymond James | → $33 | Maintains | Outperform |
03/01/2021 | 1751.85% | SVB Leerink | → $20 | Initiates Coverage On | → Outperform |
日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
---|---|---|---|---|---|
2022 年 12 月 8 日 | — | 雷蒙德·詹姆 | 降級 | 跑贏大盤 → 市場表現 | |
04/12/2022 | 29.63% | 傑富瑞集團 | 30 美元 → 1.4 美元 | 降級 | 買入 → 持有 |
03/25/2022 | 733.33% | 雷蒙德·詹姆 | 24 美元 → 9 美元 | 維護 | 跑贏大盤 |
01/03/2022 | 548.15% | 摩根大通 | 15 美元 → 7 美元 | 維護 | 中立 |
11/16/2021 | 1381.48% | SVB Leerink | 20 美元 → 16 美元 | 降級 | 跑贏大盤 → 市場表現 |
2021 年 10 月 20 日 | 4066.67% | Craig-Hallum | → 45 美元 | 啓動覆蓋範圍開啓 | → 購買 |
10/19/2021 | 4529.63% | HC Wainwright & Co. | → 50 美元 | 啓動覆蓋範圍開啓 | → 購買 |
2021 年 9 月 23 日 | 3511.11% | JonesTrading | → 39 美元 | 啓動覆蓋範圍開啓 | → 購買 |
07/30/2021 | 3140.74% | 雷蒙德·詹姆 | 33 美元 → 35 美元 | 維護 | 跑贏大盤 |
2021 年 1 月 3 日 | 2862.96% | 傑富瑞集團 | → 32 美元 | 啓動覆蓋範圍開啓 | → 購買 |
2021 年 1 月 3 日 | 1474.07% | 摩根大通 | → 17 美元 | 啓動覆蓋範圍開啓 | → 中立 |
2021 年 1 月 3 日 | 2955.56% | 雷蒙德·詹姆 | → 33 美元 | 維護 | 跑贏大盤 |
2021 年 1 月 3 日 | 1751.85% | SVB Leerink | → 20 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
Landos Biopharma Questions & Answers
Landos Biopharma 問題與解答
The latest price target for Landos Biopharma (NASDAQ: LABP) was reported by Raymond James on August 12, 2022. The analyst firm set a price target for $2.00 expecting LABP to rise to within 12 months (a possible 85.19% upside). 100 analyst firms have reported ratings in the last year.
雷蒙德·詹姆斯於2022年8月12日公佈了蘭多斯生物製藥(納斯達克股票代碼:LABP)的最新目標股價。該分析公司將目標股價定爲2.00美元,預計LABP將在12個月內升至12個月內(可能上漲85.19%)。去年有100家分析公司公佈了評級。
The latest analyst rating for Landos Biopharma (NASDAQ: LABP) was provided by Raymond James, and Landos Biopharma upgraded their outperform rating.
雷蒙德·詹姆斯對蘭多斯生物製藥(納斯達克股票代碼:LABP)的最新分析師評級由雷蒙德·詹姆斯提供,蘭多斯生物製藥上調了跑贏大盤的評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Landos Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Landos Biopharma was filed on August 12, 2022 so you should expect the next rating to be made available sometime around August 12, 2023.
分析師在進行了廣泛的研究後得出了股票評級,其中包括瀏覽公開財務報表,與Landos Biopharma的高管和客戶交談,以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級,因此每家公司每年應該獲得4次評級。Landos Biopharma的最新評級是在2022年8月12日公佈的,因此您應該預計下一個評級將在2023年8月12日左右公佈。
While ratings are subjective and will change, the latest Landos Biopharma (LABP) rating was a upgraded with a price target of $0.00 to $2.00. The current price Landos Biopharma (LABP) is trading at is $1.08, which is within the analyst's predicted range.
儘管評級是主觀的,並且會發生變化,但最新的Landos Biopharma(LABP)評級已上調,目標股價爲0.00美元,至2.00美元。蘭多斯生物製藥(LABP)目前的交易價格爲1.08美元,在分析師的預測區間內。